Stay updated with breaking news from Ludwig hantson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dedicated rare disease unit to be headquartered in Boston Geographical presence to be enhanced with broad coverage across primary, speciality and highly specialised care Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca’s broad-based revenue and the company will further globalise Alexion’s portfolio Enhanced operating margin and cash flow to enable rapid debt reduction with an ambition to increase the dividend The acquisition will be immediately core earnings-accretive and value-enhancing, and is aligned with stated capital-allocation priorities December 12, 2020 07:48 AM Eastern Standard Time – CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. ....
Alexion sale will go down as one of the biggest buyouts in Boston history Local leaders look on the bright side: AstraZenecaâs decision to base its rare-disease business here By Jon Chesto Globe Staff,Updated December 14, 2020, 7:54 p.m. Email to a Friend Reflections are seen on a sign outside the global headquarters of AstraZeneca in London. England-based pharmaceutical company AstraZeneca, which is involved in development of a COVID-19 vaccine, said during the weekend it is acquiring Boston-based drug developer Alexion Pharmaceuticals in a deal worth $39 billion.Kirsty Wigglesworth/Associated Press/File 2009 Alexion Pharmaceuticals became one of the biggest public companies in Massachusetts overnight by moving its headquarters to Boston less than three years ago. ....
AstraZenaca to Buy Rare Disease Specialist Alexion for $39 billion AstraZeneca snaps up Alexion to expand in immunology. PUBLISHED BY AstraZeneca has struck a deal to buy US rare disease specialist Alexion in a $39 billion cash-and-stock agreement. The Anglo-Swedish company has undergone quite a transformation in its fortunes after the successful announcement of its coronavirus vaccine with Oxford University. Just six years ago it was on the brink of being swallowed up by Pfizer. The company’s chief executive officer Pascal Soriot worked hard to revitalize his company’s research and development operation, but it failed to make any big strides in new drugs till its foray into cancer drugs and its recent vaccine success. ....
AstraZeneca to Acquire Alexion for $39B, Adding Rare Disease, Immunology Assets AstraZeneca signaled its intent to expand into rare disease drug development and grow into an immunology leader by announcing plans to acquire Alexion Pharmaceuticals for $39 billion, in what would be the largest biopharma acquisition of 2020.[Alexion Pharmaceuticals] December 14, 2020 AstraZeneca signaled its intent to expand into rare disease drug development and grow into an immunology leader by announcing plans to acquire Alexion Pharmaceuticals for $39 billion, in what would be the largest biopharma acquisition of 2020.[Alexion Pharmaceuticals] Share AstraZeneca signaled its intent to expand into rare disease drug development and grow into an immunology leader on Saturday when it announced plans to acquire Alexion Pharmaceuticals for $39 billion, in what would be the largest biopharma acquisition of 2020. ....
AstraZeneca $39B Acquisition of US biotech Alexion Is Well-Thought Move Dec 14 2020 · 12:57 UTC by Bhushan Akolkar · 3 min read Photo; AstraZeneca / Twitter You have successfully joined our subscriber list. As part of the massive $39 billion deal, AstraZeneca has agreed to pay a whopping 45% of the share price of Alexion. As per analysts, this could be a win-win situation for both companies. British pharmaceutical giant AstraZeneca Plc (LON: AZN) has announced one of its largest acquisitions in history. Last Saturday, December 12, the British drugmaker announced its acquisition of US biotech Alexion Pharmaceuticals. The deal closed for a massive $39 billion all in cash and stock. ....